Lunit Announces Financial Results for the First Half of 2022
* Consolidated revenue in the second quarter of 2022 increased by 190% compared to same prior-year period * Total revenue for H1 2022 amounted to KRW 5.48 billion, or 82.5% of the total revenue of last year SEOUL, South Korea, Aug. 12, 2022 /PRNewswire/ -- Lunit (KRX: 328130.KQ), a global pro...
New Immunotherapy Combination Study for Nasopharyngeal Cancer Demonstrates Effectiveness of Lunit AI as Predictive Aid in Treatment Outcome--Published in Clinical Cancer Research
* Recent clinical trial on combination immunotherapy for nasopharyngeal cancer provides evidence for Lunit SCOPE IO's ability to predict patient response. * Analysis indicates Immune-excluded Immune Phenotype acts as a resistance mechanism against combination immunotherapy, further supporting...
AI-based Cancer Solution Pioneer Lunit Makes Market Debut
SEOUL, South Korea, July 21, 2022 /PRNewswire/ -- Lunit, a global provider of AI-powered cancer solutions, announced today that it made its stock market debut on the South Korean KOSDAQ under the ticker "A32813". Lunit's initial public offering of 1,215,800 shares of its common stock was priced a...
